Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Analyst Ratings
This is a breakdown of current ratings and target prices for Fresh Tracks Therapeutics and LENZ Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
LENZ Therapeutics | 0 | 0 | 6 | 1 | 3.14 |
LENZ Therapeutics has a consensus price target of $35.40, suggesting a potential upside of 34.40%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Fresh Tracks Therapeutics.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Fresh Tracks Therapeutics | N/A | N/A | N/A |
LENZ Therapeutics | N/A | -58.48% | -55.50% |
Risk and Volatility
Fresh Tracks Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Earnings and Valuation
This table compares Fresh Tracks Therapeutics and LENZ Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Fresh Tracks Therapeutics | $10.06 million | 0.42 | -$5.69 million | ($1.41) | -0.50 |
LENZ Therapeutics | N/A | N/A | -$124.65 million | N/A | N/A |
Fresh Tracks Therapeutics has higher revenue and earnings than LENZ Therapeutics.
Insider & Institutional Ownership
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
LENZ Therapeutics beats Fresh Tracks Therapeutics on 7 of the 11 factors compared between the two stocks.
About Fresh Tracks Therapeutics
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.